8 results
The primary objectives of this study are to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for in subjects with HF and left ventricular systolic dysfunction and to characterize itspharmacokinetics (PK) after 20 weeks…
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure.Secondary:*…
Our primary objective is to elucidate the neurophysiologic effects of short-term TUS on deep brain circuits in humans. We will map the effects of TUS targeting the amygdala vs. two subregions of the thalamus (mediodorsal & pulvinar nucleus)…
To obtain additional, long term, safety data for tafamidis in subjects with transthyretin amyloid cardiomyopathy (ATTR CM). To provide investigational product, tafamidis, to ATTR CM subjects who complete 30 months of blinded treatment on protocol…
The objective of this study is to determine the efficacy, safety, and tolerability of tafamidis in subjects with transthyretin cardiomyopathy.The primary objective is to assess the efficacy, safety, and tolerability of an oral dose of 20 mg or 80 mg…
To confirm our previous findings that both TUS and auditory cuing decreases MEP amplitude in an independent sample using a more efficient design. Reducing the number of principal conditions will benefit data quality and allow for better estimation…
The primary objective is to assess the causal role of the human amygdala in fear learning, by indexing the impact of TUS targeting the amygdala on physiological markers of fear. The secondary objectives are to (1) discern the neuromodulatory effects…
Our primary objective is to translate an in non-human primate established online TUS protocol to humans. To this end, we will investigate how this protocol influences choice behaviour in humans, by stimulating the left and right FEF in a saccade…